AEterna Zentaris: Q4 Earnings Insights
AEterna Zentaris (NASDAQ:AEZS) reported its Q4 earnings results on Wednesday, March 27, 2024 at 08:05 AM. Here’s what…
Aeterna Zentaris Says US Sales Of Macrilen For Adult Use Will Be Temporarily Discontinued As Of May 23 Until Relaunch With An Alternate Commercialization Partner
U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand
AEterna Zentaris Q3 EPS $(0.70) Down From $(0.25) YoY
AEterna Zentaris (NASDAQ:AEZS) reported quarterly losses of $(0.70) per share. This is a 180 percent decrease over losses of $(0.25) per share from the same period last year.
Aeterna Zentaris Set To Regain Full Rights To Macrilen In U.S. And Canada From Novo Nordisk
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Gainers
Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.
IBM And 20 Stocks Moving Premarket
Gainers
Applied Blockchain, Inc. (NASDAQ: APLD) rose 32.1% to $1.40 in pre-market trading after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.
Aeterna Zentaris Announces Shareholder Approval Of Share Consolidation
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and